Latest News

  • FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 Diabetes Read More
  • Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2012 Read More
  • Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder Read More

Investors

Learn More

Working at Alkermes

Join Our Team